News

Stelara dose escalation effective, safe in luminal, perianal Crohn’s disease

AUSTIN, Texas — Real-world dose escalation of Stelara was safe and effective in patients with perianal Crohn’s disease, according to data presented at Crohn’s and Colitis Congress.“Standard ustekinumab dosing is every 8 weeks for moderate to severe Crohn’s disease, but in real-world practice a lot of physicians will dose escalate to every 4 or every…

News

Single-center study raises larger issues about proper billing

Two CMS codes for advanced care planning — 99497 and 99498 — were used less than 20 times at a tertiary care center in Iowa during in a nearly 3-year period, according to findings published in the Journal of the American Board of Family Medicine. Additionally, the center was successfully reimbursed only about one-quarter of…

News

Chronic inflammatory disease expenditures nearly double over last 2 decades

AUSTIN, Texas — The overall health care cost of caring for patients with inflammatory bowel disease has increased at a rapid rate over the last 20 years, according to data presented at Crohn’s and Colitis Congress.However, over the last two decades, the data demonstrate that there has been a shift in what the primary driver…